Dietary lipids and NAFLD: Suggestions for improved nutrition

Acta Gastro-Enterologica Belgica

Volumn 73, Issue 4, 2010, Pages 431-436

  Molendi Coste, O ^a   Legry, V ^a   Leclercq, I A ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Dietary recommendations; Monounsaturated fatty fatty acids; NAFLD; Poyunsaturated fatty acid; Saturated fatty acids

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPID PEROXIDE; LONG CHAIN N 3 POLYUNSATURATED FATTY ACID; MITOGEN ACTIVATED PROTEIN KINASE; MONOUNSATURATED FATTY ACID; NITROUS OXIDE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; OXYGEN RADICAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYUNSATURATED FATTY ACID; RETINOID X RECEPTOR; RIMONABANT; STEROL REGULATORY ELEMENT BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DIET THERAPY; DYSLIPIDEMIA; ENDOPLASMIC RETICULUM STRESS; ENERGY CONSUMPTION; FAT INTAKE; FOOD INTAKE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIVER BIOPSY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; REVIEW; RISK FACTOR; TREATMENT DURATION; ARTICLE; FATTY LIVER;

DIETARY FATS; FATTY ACIDS, MONOUNSATURATED; FATTY ACIDS, OMEGA-3; FATTY LIVER; HUMANS;

EID: 79952206346     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. BYRNE C.D. Fatty liver: role of inflammation and fatty acid nutrition. Prostaglandins Leukot. Essent. Fatty Acids, 2010, 82: 265-271.
2. HWU C.M., HSIUNG C.A., WU K.D., LEE W.J., SHIH K.C., GROVE J., CHEN Y.D., RODRIGUEZ B.L., CURB J.D. Diagnosis of insulin resistance in hypertensive patients by the metabolic syndrome: AHA vs. IDF definitions. Int. J. Clin. Pract., 2008, 62: 1441-1446.
3. DAS U.N. Is metabolic syndrome X an inflammatory condition? Exp. Biol. Med. (Maywood), 2002, 227: 989-997.
4. BULLO M., CASAS-AGUSTENCH P., AMIGO-CORREIG P., ARANCETA J., SALAS-SALVADO J. Inflammation, obesity and co -morbidities: the role of diet. Public Health Nutr., 2007, 10: 1164-1172.
5. FERRANTE A.W., Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J. Intern. Med., 2007, 262: 408-414.
6. LUCZYNSKI W., BOSSOWSKI A., GLOWINSKA-OLSZEWSKA B., KOS J., STASIAK-BARMUTA A. [The role of T-regulatory cells in the pathogenesis of immunological disturbances accompanying obesity and atherosclerosis]. Postepy Hig. Med. Dosw. (Online), 2010, 64: 156-160.
7. HUANG W., METLAKUNTA A., DEDOUSIS N., ZHANG P., SIPULA I., DUBE J.J., SCOTT D.K., O'DOHERTY R.M. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes, 2010, 59: 347-357.
8. LANTHIER N., MOLENDI-COSTE O., HORSMANS Y., VAN ROOIJEN N., CANI P.D., LECLERCQ I.A. Kupffer cell activation is a causal factor for hepatic insulin resistance. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 298: G107-G116.
9. LECLERCQ I.A., DA SILVA M.A., SCHROYEN B., VAN HUL N., GEERTS A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J. Hepatol., 2007, 47: 142-156.
10. VANNI E., BUGIANESI E., KOTRONEN A., DE MINICIS S., YKIJARVINEN H., SVEGLIATI-BARONI G. From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis., 2010, 42: 320-330.
11. FARRELL G.C., LARTER C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 2006, 43: S99-S112.
12. BELLENTANI S., MARINO M. Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD). Ann. Hepatol., 2009, 8 Suppl 1: S4-S8.
13. HUANG E.S., BASU A., O'GRADY M., CAPRETTA JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care, 2009, 32: 2225-2229.
14. CAVE M., DEACIUC I., MENDEZ C., SONG Z., JOSHI-BARVE S., BARVE S., MC CLAIN C. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J. Nutr. Biochem., 2007, 18: 184-195.
15. DAY C.P., JAMES O.F. Steatohepatitis: a tale of two hits? Gastroenterology, 1998, 114: 842-845.
16. NEUSCHWANDER-TETRI B.A. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology, 2010, 52: 774-788.
17. MASTERTON G.S., PLEVRIS J.N., HAYES P.C. Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. Aliment Pharmacol. Ther., 2010, 31: 679-692.
18. SHOELSON S.E., LEE J., GOLDFINE A.B. Inflammation and insulin resistance. J. Clin. Invest., 2006, 116: 1793-1801.
19. ELINAV E., PAPPO O., SKLAIR-LEVY M., MARGALIT M., SHIBOLET O., GOMORI M., ALPER R., THALENFELD B., ENGELHARDT D., RABBANI E., ILAN Y. Adoptive transfer of regulatory NKT lymphocytes ameliorates non-alcoholic steatohepatitis and glucose intolerance in ob/ob mice and is associated with intrahepatic CD8 trapping. J. Pathol., 2006, 209: 121-128.
20. HEVENER A.L., OLEFSKY J.M., REICHART D., NGUYEN M.T., BANDYOPADYHAY G., LEUNG HY., WATT M.J., BENNER C., FEBBRAIO M.A., NGUYEN AK., FOLIAN B., SUBRAMANIAM S., GONZALEZ F.J., GLASS C.K., RICOTE M. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J. Clin. Invest., 2007, 117: 1658-1669.
21. FABBRINI E., SULLIVAN S., KLEIN S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology, 2010, 51: 679-689.
22. TARANTINO G., SAVASTANO S., COLAO A. Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance. World J. Gastroenterol., 2010, 16: 4773-4783.
23. HARRISON S.A., NEUSCHWANDER-TETRI B.A. Pharmacologic management of nonalcoholic fatty liver disease. Clin. Liver Dis., 2004, 8: 715-28, xii.
24. NEUSCHWANDER-TETRI B.A. Lifestyle modification as the primary treatment of NASH. Clin. Liver Dis., 2009, 13: 649-665.
25. GORMAZ J.G., RODRIGO R., VIDELA L.A., BEEMS M. Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease. Prog. Lipid Res., 2010, 49: 407-419.
26. LINSEISEN J., WELCH A.A., OCKE M., AMIANO P., AGNOLI C., FERRARI P., SONESTEDT E., CHAJES V., BUENO-DEMESQUITA H.B., KAAKS R., WEIKERT C., DORRONSORO M., RODRIGUEZ L., ERMINI I., MATTIELLO A., VAN DER SCHOUW Y.T., MANJER J., NILSSON S., JENAB M., LUND E., BRUSTAD M., HALKJAER J., JAKOBSEN M.U., KHAW K.T., CROWE F., GEORGILA C., MISIRLI G., NIRAVONG M., TOUVIER M., BINGHAM S., RIBOLI E., SLIMANI N. Dietary fat intake in the European Prospective Investigation into Cancer and Nutrition: results from the 24-h dietary recalls. Eur. J. Clin. Nutr., 2009, 63 Suppl 4: S61-S80.
27. LUPIEN J.R., RICHMOND A., RANDELL M., COTIER J.P., GHAZALI A., DAWSON R. Food, nutrition and agriculture. Edible fats and oils. Food and Agriculture Organization of the United Nations, Agriculture and Consumer Protection Department [11], 1994.
28. SIMOPOULOS A.P. Is insulin resistance influenced by dietary linoleic acid and trans fatty acids? Free Radic. Biol. Med., 1994, 17: 367-372.
29. RUIDAVETS J.B., BONGARD V., DALLONGEVILLE J., ARVEILER D., DUCIMETIERE P., PERRET B., SIMON C., AMOUYEL P., FERRIERES J. High consumptions of grain, fish, dairy products and combinations of these are associated with a low prevalence of metabolic syndrome. J. Epidemiol Community Health, 2007, 61: 810-817.
30. ANDERSON B.M., MA D.W. Are all n-3 polyunsaturated fatty acids created equal? Lipids Health Dis., 2009, 8: 33.
31. DOLECEK T.A. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the multiple risk factor intervention trial. Proc. Soc. Exp. Biol. Med., 1992, 200: 177-182.
32. DELAVAR M.A., LYE M.S., KHOR G.L., HASSAN S.T., HANACHI P. Dietary patterns and the metabolic syndrome in middle aged women, Babol, Iran. Asia Pac. J. Clin. Nutr., 2009, 18: 285-292.
33. ZELBER-SAGI S., NITZAN-KALUSKI D., GOLDSMITH R., WEBB M., BLENDIS L., HALPERN Z., OREN R. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J. Hepatol., 2007, 47: 711-717.
34. CORTEZ-PINTO H., JESUS L., BARROS H., LOPES C., MOURA M.C., CAMILO M.E. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin. Nutr., 2006, 25: 816-823.
35. ARAYA J., RODRIGO R., VIDELA L.A., THIELEMANN L., ORELLANA M., PETTINELLI P., PONIACHIK J. Increase in long-chain polyunsaturated fatty acid n -6/n -3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. (Lond.), 2004, 106: 635-643.
36. MARTINELLI N., GIRELLI D., MALERBA G., GUARINI P., ILLIG T., TRABETTI E., SANDRI M., FRISO S., PIZZOLO F., SCHAEFFER L., HEINRICH J., PIGNATTI P.F., CORROCHER R., OLIVIERI O. FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease. Am. J. Clin. Nutr., 2008, 88: 941-949.
37. VUPPALANCHI R., CUMMINGS O.W., SAXENA R., ULBRIGHT T.M., MARTIS N., JONES D.R., BANSAL N., CHALASANI N. Relationship among histologic, radiologic, and biochemical assessments of hepatic steatosis: a study of human liver samples. J. Clin. Gastroenterol., 2007, 41: 206-210.
38. EBBESSON S.O., TEJERO M.E., NOBMANN E.D., LOPEZALVARENGA J.C., EBBESSON L., ROMENESKO T., CARTER E.A., RESNICK H.E., DEVEREUX R.B., MACCLUER J.W., DYKE B., LASTON S.L., WENGER C.R., FABSITZ R.R., COMUZZIE A.G., HOWARD B.V. Fatty acid consumption and metabolic syndrome components: the GOCADAN study. J. Cardiometab. Syndr., 2007, 2: 244-249.
39. VALLIM T., SALTER A.M. Regulation of hepatic gene expression by saturated fatty acids. Prostaglandins Leukot Essent Fatty Acids, 2010, 82: 211-218.
40. VAN DEN BERG S.A., GUIGAS B., BIJLAND S., OUWENS M., VOSHOL P.J., FRANTS R.R., HAVEKES L.M., ROMIJN J.A., VAN DIJK K.W. High levels of dietary stearate promote adiposity and deteriorate hepatic insulin sensitivity. Nutr. Metab. (Lond.), 2010, 7: 24.
41. BASU A., DEVARAJ S., JIALAL I. Dietary factors that promote or retard inflammation. Arterioscler. Thromb. Vasc. Biol., 2006, 26: 995-1001.
42. HUSSEIN O., GROSOVSKI M., LASRI E., SVALB S., RAVID U., ASSY N. Monounsaturated fat decreases hepatic lipid content in non-alcoholic fatty liver disease in rats. World J. Gastroenterol., 2007, 13: 361-368.
43. JULIUS U. Fat modification in the diabetes diet. Exp Clin Endocrinol Diabetes., 2003, 111: 60-65.
44. RODRIGUEZ-VILLAR C., PEREZ-HERAS A., MERCADE I., CASALS E., ROS E. Comparison of a high-carbohydrate and a high-monounsaturated fat, olive oil-rich diet on the susceptibility of LDL to oxidative modification in subjects with Type 2 diabetes mellitus. Diabet. Med., 2004, 21: 142-149.
45. ASSY N., NASSAR F., NASSER G., GROSOVSKI M. Olive oil consumption and non-alcoholic fatty liver disease. World J. Gastroenterol., 2009, 15: 1809-1815.
46. KOPECKY J., ROSSMEISL M., FLACHS P., KUDA O., BRAUNER P., JILKOVA Z., STANKOVA B., TVRZICKA E., BRYHN M. n-3 PUFA: bioavailability and modulation of adipose tissue function. Proc. Nutr. Soc., 2009, 68: 361-369.
47. SERHAN C.N. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J. Thromb. Haemost., 2009, 7 Suppl 1: 44-48.
48. BANNENBERG G.L. Therapeutic applicability of anti-inflammatory and proresolving polyunsaturated fatty acid-derived lipid mediators. Scientific World Journal, 2010, 10: 676-712.
49. DAS U.N. Essential Fatty acids -a review. Curr. Pharm. Biotechnol., 2006, 7: 467-482.
50. DAS U.N. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids Health Dis., 2008, 7: 37.
51. BORDONI A., DI NUNZIO M., DANESI F., BIAGI P.L. Polyunsaturated fatty acids: From diet to binding to ppars and other nuclear receptors. Genes Nutr., 2006, 1: 95-106.
52. STIENSTRA R., MANDARD S., PATSOURIS D., MAASS C., KERSTEN S., MULLER M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation. Endocrinology, 2007, 148: 2753-2763.
53. ABETE I., ASTRUP A., MARTINEZ J.A., THORSDOTTIR I., ZULET M.A. Obesity and the metabolic syndrome: role of different dietary macronutrient distribution patterns and specific nutritional components on weight loss and maintenance. Nutr. Rev., 2010, 68: 214-231.
54. DAS U.N. A defect in the activity of Delta6 and Delta5 desaturases may be a factor predisposing to the development of insulin resistance syndrome. Prostaglandins Leukot. Essent. Fatty Acids, 2005, 72: 343-350.
55. ZULIANI G., GALVANI M., LEITERSDORF E., VOLPATO S., CAVALIERI M., FELLIN R. The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias. Curr. Pharm. Des., 2009, 15: 4087-4093.
56. EBRAHIMI M., GHAYOUR-MOBARHAN M., REZAIEAN S., HOSEINI M., PARIZADE S.M., FARHOUDI F., HOSSEININEZHAD S.J., TAVALLAEI S., VEJDANI A., AZIMI-NEZHAD M., SHAKERI M.T., RAD M.A., MOBARRA N., KAZEMI-BAJESTANI S.M., FERNS G.A. Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol., 2009, 64: 321-327.
57. SIMOPOULOS A.P. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed. Pharmacother., 2002, 56: 365-379.
58. MARTIN DE SANTA O.L., SANCHEZ MUNIZ F.J., VAQUERO M.P. N-3 fatty acids in glucose metabolism and insulin sensitivity. Nutr. Hosp., 2009, 24: 113-127.
59. CAPANNI M., CALELLA F., BIAGINI M.R., GENISE S., RAIMONDI L., BEDOGNI G., SVEGLIATI-BARONI G., SOFI F., MILANI S., ABBATE R., SURRENTI C., CASINI A. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with nonalcoholic fatty liver disease: a pilot study. Aliment Pharmacol. Ther., 2006, 23: 1143-1151.
60. SPADARO L., MAGLIOCCO O., SPAMPINATO D., PIRO S., OLIVERI C., ALAGONA C., PAPA G., RABUAZZO A.M., PURRELLO F. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig. Liver Dis., 2008, 40: 194-199.
61. TANAKA N., SANO K., HORIUCHI A., TANAKA E., KIYOSAWA K., AOYAMA T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol., 2008, 42: 413-418.
62. NAKAMURA M.T, NARA T.Y. Structure, function, and dietary regulation of delta6, delta5, and delta9 desaturases. Annu. Rev. Nutr., 2004, 24: 345-376.
63. CALDER P.C. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am. J. Clin. Nutr., 2006, 83: 1505S-1519S.
64. REESE A.C., FRADET V., WITTE J.S. Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. J. Nutrigenet. Nutrigenomics, 2009, 2: 149-158.
65. ARAYA J., RODRIGO R., PETTINELLI P., ARAYA A.V., PONIACHIK J., VIDELA L.A. Decreased liver fatty acid delta-6 and delta-5 desaturase activity in obese patients. Obesity (Silver Spring), 2010, 18: 1460-1463.
66. GONZALEZ-PERIZ A., CLARIA J. Resolution of adipose tissue inflammation. Scientific World Journal, 2010, 10: 832-856.
67. YASHODHARA B.M., UMAKANTH S., PAPPACHAN J.M., BHAT S.K., KAMATH R., CHOO B.H. Omega-3 fatty acids: a comprehensive review of their role in health and disease. Postgrad. Med. J., 2009, 85: 84-90.
68. HARRIS W.S. International recommendations for consumption of long-chain omega-3 fatty acids. J. Cardiovasc. Med. (Hagerstown), 2007, 8 Suppl 1: S50-S52.
69. Interim Summary of Conclusions and Dietary Recommendations on Total Fat & Fatty Acids -From the Joint FAO/WHO Expert Consultation on Fats and Fatty Acids in Human Nutrition, November 10-14, 2008, WHO HQ, Geneva, 2008.
70. SIMOPOULOS A.P. n-3 fatty acids and human health: defining strategies for public policy. Lipids, 2001, 36 Suppl: S83-S89.
71. MOLENDI-COSTE O., LEGRY V., LECLERCQ I.A. Why and how meet n-3 PUFA dietary recommendations? Gastroenteroly Research and Practice, 2010 (in press).
72. INDART A., VIANA M., GROOTVELD M.C., SILWOOD C.J., SANCHEZ-VERA I., BONET B. Teratogenic actions of thermally-stressed culinary oils in rats. Free Radic. Res., 2002, 36: 1051-1058.
73. EATON S.B., KONNER M.J., CORDAIN L. Diet-dependent acid load, Paleolithic [corrected] nutrition, and evolutionary health promotion. Am. J. Clin. Nutr., 2010, 91: 295-297.